A Short Note On Hepatitis C And Cirrhosis

This research paper is going to review today’s silent killer, the Hepatitis C virus. This paper will talk about the description of the disease, the signs and symptoms, the etiology and risk factors, diagnostic studies, treatments and prognosis of this disease. I had lived with this disease for over ten years before diagnosed so it is important to understand the signs and symptoms so the disease can be identified and a treatment plan can be identified as the sooner it is treated the more likely it will eradicate the disease.

A few years ago, Hepatitis C was a scary term for many of us. But, today the medical problem is curable as there are various and advanced ways available. The improvement in the treatment is especially notable because experts have worked harder to obtain this success. Still, there are some significant changes are left and hopefully they will be completed soon. Presently, the HCV treatments get rid of the virus in merely slightly more than half of all sufferers. The medicines also have unnecessary side effects that make it complicated or not possible for some patients to get them. HCV medication online available, but it is not worthy to take them without the concern of the doctor.

Purpose: The purpose of the article was to address one of the interventions in Hepatitis C treatment and the temporal aspect of it in particular. The authors use a question to begin the article which makes it easy for the reader to find the purpose of the article and later the issue which would be preceding it. Within the purpose, the authors also identify their audience being the patients living with Hepatitis C virus, the insurance companies, and the health departments. Identifying the stakeholders is effective in targeting the message to the appropriate population and further adds clarity to the issue since it would be relatable to the authors of the article as well as their audience.

An overarching theme that emerged from the literature was the intersection of Indigeneity, hepatitis C and injection drug use (Craib et al., 2009). Persons who

You are correct stating educating patients on high risk behaviors such as IV drug use, sharing needles and unprotected sex greatly reduces the number on new cases that are diagnosed. One very important obstacle implementing this intervention is that healthcare “providers also have inadequate knowledge about viral hepatitis, often failing to provide at risk patients with viral hepatitis related services” (Ward, Valdiserri, & Koh, 2012, p. 559). Until we overcome improving awareness and education with the provider, reaching these at risk patients, then we can strengthen awareness in the community setting.

Hepatitis C is an infection of the blood caused by the Hepatitis C virus. While the Hepatitis virus is widely known for damage caused to the liver, it can also cause damage to the kidneys and other body organs as well since it is an infection in the blood. Hepatitis C is both acute and chronic meaning it can last 6 months and resolve on it 's own or it can last a lifetime. The family name Hepatitis includes Hepatitis A and Hepatitis B in name while each is a completely separate disease. Each separate disease is caused from a completely different virus and transmitted in differently.

Medicine is one of our most powerful assets as human-beings, it allows us to extend the life expectancy and resist disease and infection that we would not have been able to in the past. Even though there were many advancements in medicines there are still very powerful diseases such cancer, diabetes, STDs, epidemic diseases, and the forms of hepatitis. A recent breakthrough may have led to the discovery of the cure for hepatitis-C. This is very important for society in multiple forms and I believe with this discovery we as a society may be able to destroy this form of hepatitis and development new opportunities in other parts of the medical field.

Many high-risk populations have active HCV infection. It is in the best interest of these persons as well as those they might expose to the virus to be tested early and have the earliest opportunity to receive interventions. Appropriate screening for risk is the responsibility of every healthcare worker. A public health concern is that with better screening and early intervention, lives can be saved and quality of life can be improved for those who have and live

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), which can cause both acute and chronic hepatitis infection, which are the two major types of hepatitis C. Ranging in seriousness from a mild illness lasting a few weeks to a major illness that can last a lifetime, hepatitis c often leads to inflammation of the liver. It is a problem in the United States and worldwide, mostly affecting Africa and Central and East Asia. HCV is responsible for 500,000 liver related deaths each year, is the most common bloodborne pathogen, and is a leading cause of liver transplantation. More than 4 million people in the Unites States are infected and most are not even aware of their diagnosis. Also, death due to HCV infection is the most

The leading cause of liver damage due to viral hepatitis B virus and hepatitis C virus represents a major health problem in the United States. “CDC estimates that approximately 3.2 million of Americans are chronically infected with hepatitis C virus, with an estimate of 8,000 to 10,000 hepatitis C virus related deaths annually” (CDC foundation).

Hepatitis C (HCV) is a blood borne virus that can lead to chronic liver disease and liver failure. In Canada, nearly 250,000 people have an active Hepatitis C infection (Strike, Leonard, Millson, Anstice, Berkeley, & Medd, 2006). People who inject drugs (PWID) are disproportionately represented in this statistic accounting for over 66% of those infected (Strike et al., 2006). Needle sharing among PWID is oft cited as one of the leading causes of HCV transmission (Strike et al. 2006).

Hepatitis C is an inflammation of the liver’s cells and tissues caused by the hepatitis C virus (HCV).

The mission of our company is to extend and enhance human life by providing the highest-quality pharmaceutical and related healthcare products. For the cure of Hepatitis C virus, we deal in MK-5172A it is the combination of MK-5172 and MK=8742. The conventional cure for HCV virus is compound therapy with ribavirin and pegylated interferon is given for diversifying periods according to genotype. The patients suffering from genotype 1 are treated with triple therapy (ribavirin and pegylated interferon with the addition of either telaprevir or boceprevir). MK-5172 and MK-8742 FDT is currently in phase III clinical trials comparing its effect on nursed virologic response 12 weeks after treatment against

The purpose of this case study on Hepatitis C (HCV) is to come up with a process improvement plan of getting patients screened, approved, educated, and started on treatment within a 20 day period. In order to make this happen, everyone in the clinic needs to be educated on the required clinical screenings and documentation. The case study is designed for: medical assistants, pre, post, tumor, and organ management nurses, and nurse practitioners. The case study will be reviewed over the next two weeks in the liver clinic and the reason is to improve the knowledge of everyone on HCV and to know what is needed in the screening and approval process of treatment.

Hepatitis C virus (HCV) has become a major problem within the human population, affecting individuals from everywhere, but especially from poor regions. At the moment, 130 to 170 million people worldwide are infected with this virus and it keeps increasing at a rate of approximately 3.5 million people per year. (1) It is estimated that about 0.2 to 26% of the general population in different countries are chronically infected by HCV. (2)(3)